Equillium Reports Q4 and Full Year 2024 Financial Results and Provides Clinical Updates

Equillium, Inc.

Phase 3 EQUATOR study in aGVHD: primary endpoint not met, but statistically significant longer-term outcomes (CR at Day 99, duration of CR, failure-free survival).
Full year 2024 revenue $41.1M, up from $36.1M in 2023; net loss $8.1M ($0.23/share) vs $13.3M ($0.38/share) in 2023.
Cash and investments $22.6M as of Dec 31, 2024; expected to fund operations into Q3 2025.
FDA meeting requested for Accelerated Approval of itolizumab in aGVHD; feedback expected May 2025.
Positive Phase 2 data for itolizumab in ulcerative colitis: clinical remission rate 23.3% vs 10.0% placebo at 12 weeks.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.